Movement Disorders Clinical Practice最新文献_第8页

Olfactory Dysfunction-A Potential Biomarker of Neurological Involvement in Wilson's Disease. 嗅觉功能障碍-威尔森氏病神经系统受累的潜在生物标志物

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-03-01 Epub Date: 2024-12-17 DOI: 10.1002/mdc3.14303

Jan Bembenek, Agnieszka Antos, Anna Członkowska, Tomasz Litwin

引用次数: 0

Toxin for Tics: Practical Guidance for Clinicians from a Registry-Based Naturalistic Study. 毒素抽搐：临床医生从注册为基础的自然研究的实践指导。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-03-01 Epub Date: 2024-12-07 DOI: 10.1002/mdc3.14296

Tamara Pringsheim, Davide Martino

{"title":"Toxin for Tics: Practical Guidance for Clinicians from a Registry-Based Naturalistic Study.","authors":"Tamara Pringsheim, Davide Martino","doi":"10.1002/mdc3.14296","DOIUrl":"10.1002/mdc3.14296","url":null,"abstract":"Background: Botulinum toxin is a recommended treatment for tics. There is little practical guidance on the use of this treatment.Objectives: Our aim is to describe our experience using botulinum toxin injections for tics in adults. We provide information on tics treated, muscles injected, and dosages used to give practical guidance.Methods: We analyzed data from the Calgary Adult Tic Registry on tic severity, the tics and muscles injected, and dosages. We assessed treatment length, reasons for discontinuation, and concurrent medications.Results: Botulinum toxin was the most used medication for tics, received by 32 of 95 (33.7%) registry participants. Participants receiving botulinum toxin were significantly older and had significantly lower vocal tic severity and total tic severity. The most common motor tics treated were blinking, head turns, and shoulder raising. The mean length of treatment was 40.4 months.Conclusions: Botulinum toxin is an effective and well-tolerated treatment for adults with tics.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":"353-357"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantifying Social Connectedness in Parkinson's Disease: Reliability and Validity of a Clinical Assessment Toolkit. 量化帕金森病患者的社会联系：临床评估工具包的可靠性和有效性。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-03-01 Epub Date: 2024-12-13 DOI: 10.1002/mdc3.14298

David Andrés González, Michelle Hyczy de Siqueira Tosin, Tila Warner-Rosen, Christopher G Goetz

{"title":"Quantifying Social Connectedness in Parkinson's Disease: Reliability and Validity of a Clinical Assessment Toolkit.","authors":"David Andrés González, Michelle Hyczy de Siqueira Tosin, Tila Warner-Rosen, Christopher G Goetz","doi":"10.1002/mdc3.14298","DOIUrl":"10.1002/mdc3.14298","url":null,"abstract":"Background: Loneliness and isolation impact health detrimentally but are understudied in Parkinson's disease (PD). Outcome measurement properties for social connection remain unexplored in PD.Objective: To evaluate the measurement properties of six social connection outcomes in PD.Methods: We evaluated internal consistency, structural validity, and construct validity for measures of loneliness (brief UCLA Loneliness Scale [ULS3], short and long de Jong Gierveld Loneliness Scale [dJGLS], social isolation [Cohen Social Network Index-SNI total people, SNI high contact networks], and social support brief Perceived Social Support Scale [PSS]).Results: We administered measures to 178 PD participants (Mage = 67.9; 81.5% at Hoehn & Yahr stage 2). There was strong internal consistency, content validity across outcomes, and a 1-factor structure (PSS, ULS3) and a 2-factor structure (dJGLS) for two measures each.Conclusions: We provide a toolbox for clinicians and researchers studying social connection in PD.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":"358-363"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 69-Year-Old Male with Subacute Gait Disturbance-Blastocystis hominis Causing Extensive Colitis with Thiamine Deficiency. 69岁男性亚急性步态障碍-人胚囊虫引起广泛结肠炎伴硫胺素缺乏。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-28 DOI: 10.1002/mdc3.70023

Yi-Cheng Tai, Malan Edward, Chin-Hsien Lin

引用次数: 0

Polygenic Risk Score Combined with Transcranial Sonography Refines Parkinson's Disease Risk Prediction. 多基因风险评分联合经颅超声改善帕金森病风险预测。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-28 DOI: 10.1002/mdc3.70011

Mart Kals, Anu Reigo, Maris Teder-Laving, Mariliis Vaht, Tiit Nikopensius, Andres Metspalu, Toomas Toomsoo

{"title":"Polygenic Risk Score Combined with Transcranial Sonography Refines Parkinson's Disease Risk Prediction.","authors":"Mart Kals, Anu Reigo, Maris Teder-Laving, Mariliis Vaht, Tiit Nikopensius, Andres Metspalu, Toomas Toomsoo","doi":"10.1002/mdc3.70011","DOIUrl":"https://doi.org/10.1002/mdc3.70011","url":null,"abstract":"Background: Dopaminergic neuron depletion in the substantia nigra (SN) and the pathological aggregation of α-synuclein are the neuropathological hallmarks of Parkinson's disease (PD).Objectives: This study aimed to investigate the association between the polygenic risk score for PD (PD-PRS) and transcranial sonography (TCS)-measured SN hyperechogenicity to enhance the accuracy of PD susceptibility prediction.Methods: PD-PRSs were calculated for over 41,000 Estonian Biobank participants age 55+ years without a PD diagnosis. Participants in the highest and lowest PD-PRS percentiles (n = 222) underwent TCS measurements and Sniffin' sticks olfactory testing. A multivariable logistic regression model was used to examine the associations between PD-PRS, risk and prodromal markers, and SN hyperechogenicity.Results: Data from 204 participants with TCS measurements were analyzed, including 107 individuals in the high-risk PD-PRS group and 97 in the low-risk PD-PRS group. Incorporating PD-PRS group assignment improved the explained variance in SN hyperechogenicity from 17.2% to 31.9%. Participants in the low-risk PD-PRS group had 0.16 times lower odds (95% confidence interval (CI) = 0.07-0.35, P < 0.001) of developing SN hyperechogenicity compared to high-risk PD-PRS individuals. Each unit increase in the Sniffin' sticks olfactory test score was significantly associated with reduced odds of SN hyperechogenicity (adjusted odds ratio = 0.60, 95% CI = 0.47-0.78, P = 0.002).Conclusions: Our findings indicate that TCS-measured SN hyperechogenicity is associated with PD-PRS and olfactory impairment. This combined assessment may improve early diagnosis of prodromal PD by pinpointing individuals at increased risk.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Myoclonus-Ataxic Presentation of Chronic Lead Toxicity. 慢性铅中毒的一种新的肌阵挛-共济失调表现。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-27 DOI: 10.1002/mdc3.70024

Vikram V Holla, Praveen Sharma, Nitish Kamble, Ravi Yadav, Pramod Kumar Pal

引用次数: 0

Parkinson Disease-Related Phantom Dystonia in an Amputated Limb. 帕金森病导致的截肢幻觉肌张力障碍

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-26 DOI: 10.1002/mdc3.70021

Abdulmunaim M Eid, Shashika Rodrigo, Scott A Norris

引用次数: 0

Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial. 治疗帕金森病左旋多巴诱发的运动障碍的美索培坦：随机 2b 期试验。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-26 DOI: 10.1002/mdc3.70004

Angelo Antonini, Padraig O'Suilleabhain, Fabricio Stocchi, Johanna Landström, Susanna Waters, Clas Sonesson, Joakim Tedroff

{"title":"Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial.","authors":"Angelo Antonini, Padraig O'Suilleabhain, Fabricio Stocchi, Johanna Landström, Susanna Waters, Clas Sonesson, Joakim Tedroff","doi":"10.1002/mdc3.70004","DOIUrl":"https://doi.org/10.1002/mdc3.70004","url":null,"abstract":"Background: The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is a largely unmet need.Objectives: Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa-induced dyskinesia. This was a phase 2b study dose finding study to investigate efficacy and safety of 2.5 mg, 5 mg and 7,5 mg b.i.d. in a randomized controlled trial.Methods: PD patients with ≥2 hours of troublesome dyskinesia were randomized to placebo or mesdopetam twice daily for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in ON time without troublesome dyskinesia (Good ON-time) as recorded with home diaries. Secondary efficacy endpoints assessing ON phase dyskinesia were the modified UDysRS (sum of parts 1, 3 and 4) and MDS-UPDRS part 4.2.Results: Groups did not differ in change from baseline to end of study in Good ON-time. Several secondary assessments for ON phase dyskinesia such as the modified UDysRS showed clinically relevant and statistically significant improvements for the 2.5 and 7.5 mg doses. OFF time showed dose dependent decrease with highest efficacy for the 7.5 mg dose. The adverse event profile was similar to placebo.Conclusions: In this study mesdopetam failed to increase Good ON-time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5 mg b.i.d. to be the preferred dose for further study.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Neuropsychiatric Decline in a Parkinson's Disease Patient with a Severe GBA1 Mutation Following Bilateral GPi Deep Brain Stimulation. 双侧GPi脑深部刺激后伴有严重GBA1突变的帕金森病患者的急性神经精神衰退

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-24 DOI: 10.1002/mdc3.70015

Vijay G Palakuzhy, Gian D Pal, Mitra Afshari

引用次数: 0

Intrafamilial Variability in WARS2-Related Disorder: A Family Case. wars2相关疾病的家族内变异：一个家族病例。

IF 2.6 4区医学

Movement Disorders Clinical Practice Pub Date : 2025-02-24 DOI: 10.1002/mdc3.70018

Federica Graziola, Federica Rachele Danti, Giorgia Segre, Morgana Fregonese, Rossella Izzo, Eleonora Lamentea, Daniele Ghezzi, Anna Ardissone, Giovanna Zorzi

引用次数: 0